ESMO TAT 2023 | Enhancing clinical models for developing novel brain tumor therapies

Igor Vivanco, PhD, King’s College London, London, UK, comments on strategies to improve current clinical models for brain tumors. Future models must enable detailed examination of the interaction between the drug and its target, and improvements in molecular models may bypass the need for animal testing. This interview took place at the ESMO Targeted Anticancer Therapies (TAT) Congress 2023 in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.